Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tessa Romero
JPMorgan Chase & Co, Research Division

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I’m one of the senior biotech analysts here at JPMorgan. We’re very pleased to be kicking off the conference with Scholar Rock. And presenting on behalf of the company, we have Chairman and CEO, David Hallal. David, over to you.

David Hallal
CEO & Chairman of the Board

Thank you very much, Tess. It’s great to be kicking off the JPMorgan conference early on a Monday morning, and we are super excited for our week here in San Francisco as well as 2026, which will be a transformative year for the company. I want to thank Tess, JPMorgan, everybody here in the room in California East as well as many, many others that are tuning in remotely via webcast.

Scholar Rock is in a position of strength as we enter 2026. We are the world leaders in myostatin biology. And with that capability, we are shaping the future of treatment for patients living with rare neuromuscular disorders. For the past 7, 8 years, we’ve been focused on developing our highly innovative monoclonal antibody, apitegromab, for children and adults living with SMA. It is the first myostatin inhibitor that has ever delivered a successful pivotal Phase III study, and it’s the only muscle-targeted treatment to demonstrate clinically meaningful benefit for patients living with SMA.

Based on the